On Apr. 22, 2005, Sanofi Pasteur announced the U.S. Food and Drug Administration (FDA) had granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include a two-dose schedule for infants and children 9 months through 23 months of age.

This was the first U.S. approval of a meningococcal vaccine for this age group.